Skip to main content

Emily Estrada

FDA Approval
02/12/2025
On February 11, 2025, the US Food and Drug Administration approved brentuximab vedotin with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-Cell lymphoma.
On February 11, 2025, the US Food and Drug Administration approved brentuximab vedotin with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-Cell lymphoma.
On February 11, 2025, the US...
02/12/2025
Oncology
News
02/10/2025
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel treatment demonstrated improved outcomes compared with idecabtagene vicleucel treatment for relapsed/refractory multiple myeloma according to a retrospective observational study.
Ciltacabtagene autoleucel...
02/10/2025
Oncology
News
02/07/2025
Talquetamab plus teclistamab therapy for relapsed/refractory multiple myeloma demonstrated durable responses among patients, however, risk for grade 3 or 4 infections were higher than either therapy alone, according to a recent study.
Talquetamab plus teclistamab therapy for relapsed/refractory multiple myeloma demonstrated durable responses among patients, however, risk for grade 3 or 4 infections were higher than either therapy alone, according to a recent study.
Talquetamab plus teclistamab...
02/07/2025
Oncology
FDA Approval
02/07/2025
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
News
02/07/2025
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with...
02/07/2025
Oncology
News
01/31/2025
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3...
01/31/2025
Oncology
News
01/31/2025
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with...
01/31/2025
Oncology
News
01/24/2025
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent...
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent...
Higher levels of BCL-2...
01/24/2025
Oncology
News
01/24/2025
According to results from a dose escalation phase 1 study, combination belinostat and pevonedistat therapy for relapsed/refractory acute myeloid leukemia or high-risk MDS demonstrated some activity and limited toxicity.
According to results from a dose escalation phase 1 study, combination belinostat and pevonedistat therapy for relapsed/refractory acute myeloid leukemia or high-risk MDS demonstrated some activity and limited toxicity.
According to results from a dose...
01/24/2025
Oncology
News
01/24/2025
Olutasidenib and azacitidine combination therapy for relapsed/refractory acute myeloid leukemia demonstrated durable patient responses and safety.
Olutasidenib and azacitidine combination therapy for relapsed/refractory acute myeloid leukemia demonstrated durable patient responses and safety.
Olutasidenib and azacitidine...
01/24/2025
Oncology